Wallace Capital Management’s AbbVie ABBV Stock Holding History

Wallace Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$545K	Buy	2,165 +489	+29%	+$105K	0.06%	53
2026 Q1	$365K	Sell	1,676 -113	-6%	-$25.1K	0.04%	56
2025 Q4	$409K	Hold	1,789	–	–	0.05%	54
2025 Q3	$414K	Hold	1,789	–	–	0.05%	55
2025 Q2	$332K	Hold	1,789	–	–	0.05%	56
2025 Q1	$375K	Buy	1,789 +3	+0.2%	+$583	0.05%	58
2024 Q4	$317K	Hold	1,786	–	–	0.04%	59
2024 Q3	$353K	Buy	1,786 +573	+47%	+$107K	0.05%	63
2024 Q2	$208K	Buy	+1,213	New	+$201K	0.03%	72
2016 Q1	–	Sell	-4,106	Closed	-$243K	–	54
2015 Q4	$243K	Buy	+4,106	New	+$236K	0.05%	50
2015 Q3	–	Sell	-3,385	Closed	-$227K	–	54
2015 Q2	$227K	Buy	+3,385	New	+$221K	0.04%	53
2015 Q1	–	Sell	-3,381	Closed	-$221K	–	55
2014 Q4	$221K	Buy	+3,381	New	+$213K	0.04%	51

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wallace Capital Management's ABBV Position: Q2 2026 in Review

Wallace Capital Management increased its AbbVie (ABBV) stake by 29% in Q2 2026, buying an estimated $105K and bringing the position to 2,165 shares worth $545K. The position accounts for 0.06% of the portfolio, ranked #53.

Wallace Capital Management first reported a position in ABBV in Q4 2014 and has held it in 12 quarters since. 4,225 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Wallace Capital Management held 2,165 shares of AbbVie worth $545K as of Q2 2026.
Wallace Capital Management bought 489 AbbVie shares in Q2 2026, an estimated $105K.
AbbVie made up 0.06% of Wallace Capital Management's portfolio in Q2 2026, its #53 holding.
Wallace Capital Management first reported a position in AbbVie in Q4 2014 and has held it in 12 quarters since.
4,225 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Wallace Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.